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reatment of
rug-Eluting Stent Restenosis
he New Pilgrimage: Quo Vadis?*
ernando Alfonso, MD, PHD
adrid, Spain
he treatment of patients with in-stent restenosis (ISR)
emains a challenge and represents a major clinical problem
1,2). Bare-metal stents (BMS) are still widely used during
oronary interventions, and the treatment of patients with
MS-ISR continues to represent a frequent problem in
veryday clinical practice. In addition, drug-eluting stents
DES) are not immune to ISR, especially when used with
off-label” indications in complex clinical and anatomic
ettings (3). Notably, some registries suggest that despite a
onsiderable increment in DES penetration, the total “re-
tenosis activity” has remained unaltered in most catheter-
zation laboratories around the world, and in fact, the
bsolute annual number of these procedures continues to
ise (3). This scenario is further complicated by recent
vidence suggesting that ISR should not be considered just
nuisance without clinical consequences (4–8). Presenta-
ion of ISR is no longer considered as benign as previously
hought, perhaps partially as a result of the widespread use
f highly sensitive markers of myocardial necrosis. Likewise,
he management of ISR also appears to pay a price in the
ong-term clinical outcome of affected patients (4–8).
See page 2710
DES-ISR is quite different from BMS-ISR (4–8). Tem-
oral presentation, morphologic patterns, underlying mech-
nisms, tissue composition, and response to treatment
haracteristically differ. As compared with BMS-ISR, the
ccurrence of DES-ISR tends to spread over a delayed time
nterval (4,5). The angiographic pattern of ISR is also
issimilar and appears to be related to DES type. In most
nstances, a “focal” pattern of ISR is detected on angiogra-
hy whereas diffuse or proliferative patterns are rare (5).
ocal patterns are more prevalent after sirolimus-eluting
tents (SES) than after paclitaxel-eluting stents (PES).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.f
From Interventional Cardiology, Cardiovascular Institute, San Carlos University
ospital, Madrid, Spain.estenosis confined to the stent edges is quite characteristic,
eading to a “candy wrapper” effect at the end of the
pectrum (4). This problem persists despite the awareness
y the interventional cardiology community of the “geo-
raphic miss” phenomenon and systematic efforts to com-
letely cover the entire injured segment.
On quantitative angiography, late lumen loss after BMS
ollows a characteristic Gaussian distribution whereas dis-
ribution of late lumen loss after DES tends to be highly
kewed, suggesting potentially different underlying patho-
hysiological mechanisms (1,2). That creates an additional
ifficulty when comparing DES studies whenever means,
nstead of median values, are used to express late angio-
raphic results. Furthermore, mechanistically, DES-ISR
ends to be associated with some unique, salient features.
ndeed, severe stent underexpansion is frequently detected
n these patients (6), whereas this phenomenon appears to
lay a less relevant role in BMS-ISR. Likewise, strut
ractures have been suggested as rare but potentially impor-
ant underlying causes of DES failure. Moreover, since the
awn of the DES era, the concept of drug failure/resistance
as emerged as a new clinical entity (8–10).
Finally, the composition of tissue obstructing the stent
lso appears to be different. In contradistinction with the
onomorphic pattern of neointimal tissue seen after BMS-
SR, a distinct, relatively heterogeneous substrate may be
etected in some patients with DES-ISR (4,7). In fact, the
resence of true atherosclerotic changes within the stent
including necrotic core development) has been occasionally
eported after DES. However, whether these unique find-
ngs are inherently related to DES-ISR or merely reflect our
urrent superior diagnostic accuracy to unravel tissue com-
osition, and whether these distinct features have clinical
mplications, warrant further investigation.
Treatment of patients with BMS-ISR has been exten-
ively studied (1,2). After a decade-long “pilgrimage in the
esert” revisiting the potential value of all different mechan-
cal interventional strategies, eventually brachytherapy
merged as a powerful effective tool in this scenario. This
echnique, however, was cumbersome to use and had
nherent limitations and logistics constraints, explaining
hy it was soon happily abandoned (perhaps prematurely)
nce DES became available. Subsequent studies clearly
emonstrated that DES are not only user-friendly but also
uch more effective than brachytherapy in this setting and,
herefore, currently are enthroned as the cornerstone in the
reatment of BMS-ISR (1,2).
Conversely, data on therapeutic options in patients with
ES-ISR remain scarce and based on small, retrospective
tudies (8–15). The information currently available, how-
ver, suggests that this new entity is even more challenging
o treat than BMS-ISR. Clinical recurrences after interven-
ions for DES-ISR are roughly 2-fold of those seen after
MS-ISR treatment (8). In addition, the therapy of choiceor patients with DES-ISR remains unknown. Fortunately,
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Treatment of DES Restenosis June 15, 2010:2717–20n this issue of the Journal, Mehilli et al. (16) present the
rst randomized trial ever performed in patients with
ES-ISR. Using a well-designed protocol, patients with
ES-ISR were randomly assigned either to repeat SES
mplantation or to PES. Results were satisfactory and
imilar in both arms. However, should we just feel
atisfied and relaxed by embracing the systematic use of
ES (with either a homo- or hetero-DES strategy) in
atients with DES-ISR, or are we skipping some impor-
ant steps in this new journey? In other words, can we do
uch better from a preventive, diagnostic, and therapeu-
ic point of view?
revious Observational Studies
lthough DES dramatically reduced the risk of ISR, this
roblem has not been eradicated. Surprisingly, there is a
aucity of studies addressing the management of DES-ISR
8–15), explaining why interventional cardiologists fre-
uently face major therapeutic dilemmas. Herewith, we will
riefly elaborate on the evidence supporting the use of DES
or DES-ISR. The study by Lemos et al. (9) was the first to
eport high rates of recurrent restenosis after treatment of
ES-ISR (43% overall, 29% after repeat DES, 18% in de
ovo DES-ISR treated with DES). Similar findings were
btained by Kim et al. (10), who suggested that SES for
ES-ISR were associated with lower recurrent restenosis
ates as compared with conventional strategies. Other stud-
es, however, showed conflicting results, with similar recur-
ence rates after balloon angioplasty and repeat DES im-
lantation (5). The relatively poor results obtained for
atients with DES-ISR (9–11) suggested that DES-ISR
licited a more adverse biologic response as compared with
MS-ISR, thus requiring an aggressive treatment. There-
ore, despite the lack of robust data supporting the superi-
rity of repeat DES implantation over alternative modali-
ies, the “sandwich” DES strategy was considered by many as
he default therapy for DES-ISR, probably due to infer-
nces from results in BMS-ISR (1,2). Furthermore, the
ationale for a “switch” strategy (hetero-DES approach),
elies on the concept of drug failure and on the different
echanisms of action of drugs currently available in DES.
owever, sound scientific evidence on this issue is still
issing. Five observational studies (11–15) provided infor-
ation on the results of the switch strategy as compared
ith homo-DES implantation. These studies were highly
eterogeneous but altogether included 487 patients (279
omo-DES, 208 hetero-DES). Equivalent clinical and
ngiographic results were found in all the studies, although
of them (15) suggested a potential benefit of the switch
odality. The GISE-CROSS study, a prospective study
urrently ongoing in Italy, is specifically addressing this
uestion. Clearly, when assessing the switch strategy, theury is still out. oresent Study
n the ISAR-DESIRE 2 (Intracoronary Stenting and An-
iographic Results: Drug-Eluting Stents for In-Stent Re-
tenosis) trial (16), 450 patients with clinically significant
ES-ISR were randomly assigned to either SES (n  225;
ypher, Cordis, Miami Lakes, Florida) or PES (n  225;
axus, Boston Scientific, Natick, Massachusetts). The pri-
ary end point of the study—late lumen loss—was similar
n both groups (mean 0.40  0.65 mm and 0.38  0.59
m, respectively; p  0.85). Other surrogate angiographic
arameters of antirestenotic efficacy, including minimal
uminal diameter at follow-up (1.93  0.73 mm vs. 1.94 
.67 mm) and binary restenosis rate (19.6% vs. 20.6%) were
lso similar and translated into equivalent rates of target
essel revascularization (16.6% vs. 14.6%). Safety data were
lso comparable, and rates of definitive stent thrombosis
0.4%) were identical in the 2 arms. The authors should be
ommended for this important, prospective, controlled
tudy that provides unique insights into the treatment of
atients with DES-ISR.
Some interesting study-related issues should be under-
ined. First, notably, as many as 90% of potentially eligible
atients with SES-ISR (from among 499 screened patients)
ere actually enrolled by these 2 large Munich centers
ecause of broad inclusion criteria, ensuring the study’s
xternal validity. Patients with complex patterns of ISR
occlusive or very diffuse ISR requiring multiple DES) were
ot excluded, thus enriching the population and reinforcing
he representation of “real-world” patients with DES-ISR.
erhaps the only concern in this regard was the inclusion of
different SES with ISR, 1 of which (polymer-free ISAR-
ES) is not widely available and accounted for two-thirds of
he patients in the trial. Nevertheless, when study results
ere reanalyzed taking into consideration the underlying
ES (Cypher vs. ISAR-SES), no differences were detected
n the relative efficacy estimates. Furthermore, the study’s
nternal validity is reassured by its rigorous methodology
nd the consistent findings demonstrated in all pre-specified
ubgroup analyses.
Second, the authors suggest that drug resistance at the
ndividual patient level could have played some role in the
igher than expected late loss found after SES. However, in
act, the study was initially designed under this hypothesis,
onsidering the superiority design in favor of PES (sample
ize calculation with an estimated late loss of 0.60 and 0.40
m after SES and PES, respectively). This indicates that a
ajor reduction in the efficacy of SES was already expected
n this scenario. That might be considered as surprising,
rstly, because previous studies by these investigators con-
istently demonstrated a significantly lower late loss after
ES than after PES, and secondly, because of the lack of
ata supporting the drug resistance issue in the clinical
etting. In particular, we should keep in mind that in the
SAR-DESIRE 1 study (1), in-stent median late loss was
nly 0.10 and 0.26 mm after SES and PES, respectively.
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June 15, 2010:2717–20 Treatment of DES Restenosisherefore, the most likely explanation for this assumption
ould had been the “fear” of sirolimus hyporesponsiveness
n patients already presenting with SES failure. As sug-
ested, additional efforts are required to identify, before-
and, potential nonresponders to specific drugs.
Third, when the 2 ISAR-DESIRE studies (1,16) are
ompared, it is clear that both SES and PES produce worse
n-stent long-term angiographic results in patients with
ES-ISR (including late loss, diameter stenosis, and min-
mal lumen diameter). Although the results of the in-
egment analysis were also slightly worse after DES-ISR, it
hould be noted that in the ISAR-DESIRE 2 trial, in-stent
ate loss was larger than in-segment late loss, whereas the
pposite was true in the ISAR-DESIRE 1 trial (1,16).
hether this finding reflects technical subtleties in quanti-
ative angiographic analyses or, rather, indicates real differ-
nces in stenting techniques or, more importantly, in the
licited vascular response remains to be determined. Any-
ay, every effort should be made to ensure optimization of
he final results—including the stent edges—in patients
ith DES-ISR.
Fourth, in this study, intravascular ultrasound (IVUS)
as not used to exclude the presence of severe DES
nderexpansion or the rare occurrence of stent fracture as
he harbinger of DES failure. Many investigators, however,
uggest that IVUS is a valuable tool to unravel underlying
echanical causes—which demand specific treatments—
nd to optimize final results (4,6). Accordingly, the routine
se of IVUS has been advocated during these repeated
nterventions to allow individualized, tailored therapies. In
his regard, one wonders whether the final pressures used in
he study (mean maximal pressure 15.5 atm) might have
een too conservative to tackle potentially underexpanded
tents. Likewise, data on pre-dilation/post-dilation strate-
ies would have been of major interest. However, the
xcellent angiographic results obtained immediately after
he procedure (11% of diameter stenosis in both arms)
rgues against the possibility of suboptimal deployment.
evertheless, we should keep in mind that angiography may
e completely misleading in this regard. Accordingly, fur-
her studies should investigate whether IVUS-guided, high-
ressure, repeat DES implantation is associated with im-
roved clinical and angiographic outcomes as compared
ith angiographic guidance alone.
Fifth, angiographic follow-up was performed at 6 to 8
onths. After DES implantation, the possibility of ongoing
rosion of luminal caliber beyond this time frame should be
onsidered. However, the 1-year clinical follow-up did not
uggest any significant catch-up phenomenon. In fact, after
he scheduled late angiography, the event rate was very low,
nd curves tended to flatten and run parallel in both arms.
Finally, the protocol stated that clopidogrel therapy had
o be maintained for at least 6 months only. This could be
onsidered insufficient in the light of current recommenda-
ions to prolong this therapy for at least 1 year. Nonetheless,
wo-thirds of patients continued this therapy for 1 year. In Rddition, the low rate (0.4%) of definitive stent thrombosis
n the 2 arms is highly reassuring. This information is
articularly valuable because some have warned against the
se of DES sandwich strategies, suggesting that this might
elay endothelialization (as the result of excessive concen-
rations of the same drug or the synergistic effects of
ifferent drugs) potentially increasing thrombotic risks
8,14). Fortunately, all of these concerns were virtually
issipated by the present study. Nevertheless, a longer
ollow-up would be of value to confirm the safety and
fficacy of the sandwich DES approach.
urning Issues
ES have reached the status of antirestenosis “icons” in the
indset of most cardiologists. Therefore, the appearance of
ES-ISR in a given patient represents the paradigm of
failure.” It constitutes a painful reminder that our knowl-
dge remains largely limited, and that we should keep
ghting ISR from bench to bedside. New insights at the
olecular level are needed to better understand the patho-
hysiology of drug failure in DES-ISR. Meanwhile, efforts
o optimize final results, pursuing ideal geometrical models,
hould be maintained, considering the high prevalence of
nderlying mechanical problems. Hopefully, these pathways
mechanistic vs. pathophysiologic) will eventually converge
nd lead to improved results.
Many DES are currently available, thus broadening the
andscape of coronary interventions. Polymer-mediated in-
ammatory reaction may act as a potential stimulus for
eointimal growth, and therefore DES with biodegradable
olymers or polymer-free might be of value. The number of
otential combinations of DES to treat ISR of specific DES
ill grow exponentially. In the study of Mehilli et al. (16),
nly patients with SES-ISR were included and only 2
rst-generation DES were analyzed. Whether ISR of new
ES will benefit from a switch strategy (as proof of
oncept) and whether second-generation DES will be more
ffective in this setting remain to be elucidated.
Finally, alternatives to recurrent implantation of metallic
ayers in the vessel wall (“onion skin” strategy) to address
ecalcitrant ISR, are eagerly awaited. Concerns about stent
nderexpansion are particularly worrisome in this scenario
17). Although initial experiences with the implantation of
third metal layer in patients with recurrent ISR are
ssociated with favorable mid-term clinical and angio-
raphic outcomes (17), larger series of patients with ex-
ended follow-up are required to confirm these results.
rug-eluting balloons are highly appealing in this regard,
ut their efficacy has only been demonstrated after BMS-
SR (18,19). Two randomized studies, also from Germany,
emonstrated the impressive antirestenotic efficacy of
aclitaxel-eluting balloons in patients with BMS-ISR
18,19). Further, 2 ongoing randomized clinical trials—
SAR-DESIRE 3 (in patients with limus-DES-ISR), and
IBS-IV (in patients with any DES-ISR)—will establish
t
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Treatment of DES Restenosis June 15, 2010:2717–20he value of drug-eluting balloons in patients with DES-
SR. The final resource to avoid escalating toward a multi-
ayered metallic vessel wall will be bioabsorbable DES.
urrently, however, that should be considered a dream
ather than a reality because of the lack of data from patients
ith ISR.
inal Remarks
here are we going now? To avoid chaotic wandering and
ventually getting lost in winding roads, pilgrims should
ollow clear recommendations. Only carefully designed
tudies and, particularly, randomized controlled trials will be
ble to shed the required light on the elusive and challeng-
ng clinical problem of DES-ISR. The study of Mehilli et
l. (16) provides a secure platform to advance our knowledge
nd to guide our next steps in this new, impassioned,
cientific journey.
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